by Michael Fenimore | Dec 15, 2022 | Uncategorized
Assessment and treatment of pain are challenges for healthcare providers and health systems. Treatment with opioid medications can decrease pain functionality but also may result in opioid tolerance, dependence, misuse, and overdose. It is important that opioids be...
by Michael Fenimore | Dec 9, 2022 | Uncategorized
New data regarding the use of anti-vascular endothelial growth factor (VEGF) prophylaxis in patients with moderate to severe nonproliferative diabetic retinopathy without diabetic macular edema underscore the need for an evidence-based shift to proactive diabetic...
by Michael Fenimore | Nov 18, 2022 | Diabetes, Endocrinology
This curriculum focuses on improving outcomes for patients with T2DM who are likely to benefit from the addition of a newer insulin, such as an MTI, to their therapeutic regimen and improving the delivery of telehealth services to underserved patients with T2DM via a...
by Michael Fenimore | Oct 27, 2022 | Uncategorized
Colorectal cancer (CRC) continues to be the second most lethal cancer in the United States (US) with approximately 149,500 new cases and 52,980 deaths per year. Patients diagnosed at an advanced/metastatic stage have a five-year survival rate of roughly 14%. For these...
by Michael Fenimore | Oct 21, 2022 | Uncategorized
This interactive program updates learners on the latest guideline recommendations for biomarker identification and application in NSCLC. The program will enable learners to select appropriate personalized treatment pathways based on the tumor profile, while...
